Peer Review reports
From: Nirmatrelvir/ritonavir treatment and the risk of post-COVID condition over 180 days in Malaysia
| Original Submission | ||
|---|---|---|
| 31 May 2024 | Submitted | Original manuscript |
| 3 Jun 2024 | Author responded | Author comments - Ee Vien Low |
| 13 Jun 2024 | Reviewed | Reviewer Report |
| 14 Jun 2024 | Reviewed | Reviewer Report |
| 12 Jul 2024 | Author responded | Author comments - Ee Vien Low |
| Resubmission - Version 2 | ||
| 3 Jun 2024 | Submitted | Manuscript version 2 |
| 14 Jul 2024 | Author responded | Author comments - Ee Vien Low |
| Resubmission - Version 3 | ||
| 14 Jul 2024 | Submitted | Manuscript version 3 |
| 15 Jul 2024 | Author responded | Author comments - Ee Vien Low |
| Resubmission - Version 4 | ||
| 15 Jul 2024 | Submitted | Manuscript version 4 |
| 23 Jul 2024 | Reviewed | Reviewer Report |
| 27 Jul 2024 | Reviewed | Reviewer Report |
| Resubmission - Version 5 | ||
| Submitted | Manuscript version 5 | |
| Publishing | ||
| 29 Jul 2024 | Editorially accepted | |
| 5 Aug 2024 | Article published | 10.1186/s12879-024-09679-1 |
You can find further information about peer review here.